Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sonoma Pharmaceuticals, Inc. engages in the development and production of hypochlorous acid (HOCl) products for wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sonoma Pharmaceuticals, Inc. – SNOA

LOS ANGELES--(BUSINESS WIRE)---- $SNOA #SNOA--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

Sonoma Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

Los Angeles, California--(Newsfile Corp. - November 25, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or "the Company") (NASDAQ: SNOA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sonoma filed an 8-K with the SEC on November 17, 2020....

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially...

ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA

LOS ANGELES--(BUSINESS WIRE)---- $SNOA #SNOA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma's "unaudited condensed consolidated...

ROSEN, RESPECTED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma's “unaudited condensed consol

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its second fiscal quarter and six months ended September 30, 2020. It further announced that it had to restate its first quarter financial statements for the quarter en

Sonoma Pharmaceuticals Reports Second Quarter FY 2021 Financial Results

Clorox

Cantel Medical

Ecolab

Kimberly-Clark

Neogen

The Covid-19 pandemic has given a significant boost to many industries such as manufacturers of gloves, masks, sanitizers, PPE (personal protective equipment), health insurance providers, and many more related areas.

These Surface Disinfectant Stocks Have Strong Upside Potential

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals and MicroSafe Group Announce that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure

Sonoma Pharmaceuticals and Te Arai BioFarma Announce Launch of Two New Microcyn® Technology Products in Australia – Nasocyn® Nasal Care and Oracyn® Oral Care

Sonoma Pharmaceuticals Reports First Quarter 2021 Financial Results

Sonoma Pharmaceuticals (SNOA) is in the news Wednesday after an update concerning its Microsafe disinfectant sent SNOA stock soaring.
The post Sonoma Pharmaceuticals News: Why SNOA Stock Is Skyrocketing 40% Today appeared first on InvestorPlace.

Sonoma Pharmaceuticals News: Why SNOA Stock Is Skyrocketing 40% Today

Sonoma Pharmaceuticals and MicroSafe Group Announce That Microsafe® Disinfectant & Sanitizer Manufactured Using Sonoma’s Microcyn® Technology Successfully Passed Material Compatibility Testing for Both Airbus and Boeing Commercial Transport Aircraft

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions today announced financial results for fiscal year 2020 and the fourth quarter ended March 31, 2020. “We began this fiscal year with a goal of reducing our losses and cash burn and are pleased with an 75% drop in our net loss whil

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2020 Financial Results

Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday. The company announced that its Nanocyn Disinfectant & Sanitizer has received approval to be entered into the Australian register of therapeutic goods to be used for use against coronavirus.

Why Sonoma Pharmaceuticals Is Trading Higher Today

Sonoma Pharmaceuticals (SNOA) is in the news Friday after approval for a disinfectant of the novel coronavirus sent SNOA stock skyrocketing.
The post Sonoma Pharmaceuticals News: SNOA Stock Skyrockets 117% on COVID-19 Disinfectant appeared first on InvestorPlace.

Sonoma Pharmaceuticals News: SNOA Stock Skyrockets 117% on COVID-19 Disinfectant

Shares of Sonoma Pharmaceuticals Inc. SNOA, +216.63% nearly tripled on heavy volume in premarket trading Friday

Sonoma Pharmaceuticals stock nearly triples after disinfectant allowed to carry COVID-19 label in Australia

PETALUMA, Calif., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin and wound conditions, is pleased to announce that it successfully closed on an asset purchase agreement for certain wound care, disinfection and animal health care products in the Middle East, Australia and Europe for $1.1 million with MicroSafe Group.

Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group

PETALUMA, Calif., Jan.  23, 2020  (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, today announced that it has commenced a process to explore and evaluate strategic alternatives for its U.S. Dermatology Division and has engaged Maxim Group LLC as its financial advisor to assist in this process.  The Company does not have a defined timeline for such a transaction and cannot provide any assurance whether or when any transaction will be announced or consummated.

Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division

PETALUMA, Calif., Nov.  29, 2019  (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the closing of a public offering of 446,577 shares of common stock at a public offering price of $3.50 per share.

Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock

PETALUMA, Calif., Nov.  26, 2019  (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of its previously announced “best efforts” public offering of shares of its common stock at a public offering price of $3.50 per share, with anticipated gross proceeds of $1.6 million, before deducting placement agent fees and offering expense payable by the Company. The offering is expected to close on or about November 29, 2019, subject to regulatory approval and customary closing conditions.

Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock

PETALUMA, Calif., Nov.  25, 2019  (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the launch of a “best efforts” public offering of shares of its common stock.

Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock

Agreement with CEO and Interim CFO Bubba Sandford ends  Amy Trombly Appointed as Interim CEO   John Dal Poggetto Appointed as New CFO

News for Sonoma Pharmaceuticals Stock (SNOA)